RTP Mobile Logo
Oncology Today with Dr Neil Love: Management of Localized Non-Small Cell Lung Cancer (Video Interview)
Released September 2022

Featuring an interview with Dr Heather Wakelee. Published September 26, 2022. (Video Interview)

CE Information and Faculty Disclosures

    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-small cell lung cancer.


    • Assess the anticipated benefits, risks and long-term outcomes associated with the use of adjuvant and neoadjuvant therapy for Stage IB-IIIA non-small cell lung cancer (NSCLC), and consider this information when counseling patients regarding current therapeutic recommendations.
    • Analyze the biologic basis for the investigation of immune checkpoint inhibitors for nonmetastatic NSCLC and evaluate available data documenting the efficacy and safety of anti-PD-1/PD-L1 antibodies as neoadjuvant or adjuvant therapy.
    • Appreciate available Phase III findings with the use of an anti-PD-1/PD-L1 antibody following the completion of chemotherapy and surgery for resectable NSCLC, and consider the potential effect of this information on current and future clinical practice.
    • Evaluate published clinical research data with EGFR-directed therapy as adjuvant treatment for localized EGFR mutation-positive non-small cell lung cancer (NSCLC), and identify patients for whom this novel approach would be warranted.
    • Recognize adverse events and other common side effects associated with anti-PD-1/ PD-L1 antibodies for early-stage NSCLC, and understand the supportive strategies available to minimize and manage these toxicities.
    • Recall the design of ongoing clinical trials evaluating novel investigational strategies for patients with localized NSCLC, and counsel appropriate patients about availability and participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Presentation Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Heather Wakelee, MD
    Professor of Medicine
    Chief, Division of Oncology
    Interim Medical Director, Stanford Cancer Center
    Deputy Director, Stanford Cancer Institute
    President, International Association for the Study of Lung Cancer (IASLC)
    Stanford, California

    Advisory Board: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen, Biotech Inc, Merck, Mirati Therapeutics Inc; Research Funding: ACEA Biosciences Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Genentech, a member of the Roche Group, Helsinn Healthcare SA, Merck, Novartis, Seagen Inc, Xcovery.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by an educational grant from Genentech, a member of the Roche Group, and Merck.

    Release date: September 2022
    Expiration date: September 2023

Acknowledge and close

Watch video
(WIFI is recommended for best performance):